GenVec, Inc., is a biopharmaceutical company developing therapeutic drugs for cancer and vaccines for infectious diseases including HIV, malaria and influenza.

According to the Complaint, this action stems from a Proposed Transaction announced on January 24, 2017, pursuant to which GenVec will be acquired by Intrexon Corporation and Intrexon GV Holding, Inc. (together, “Intrexon”). On January 24, 2017, GenVec’s Board of Directors caused the Company to enter into an agreement and plan of merger with Intrexon.

On March 17, 2016, Defendants filed a Form S-4 Registration Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges the Registration Statement, which recommends that GenVec’s stockholders vote in favor of the Proposed Transaction, omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.

This case was voluntarily dismissed on April 19, 2017.